References
- Moller HJ, Broich K. Principle standards and problems regarding proof of efficacy in clinical psychopharmacology. Eur Arch Psychiatry Clin Neurosci. 2010 Feb;260(1):3–16.
- Papakostas GI, Fava M. Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol. 2009 Jan;19(1):34–40.
- Rutherford BR, Rose SA, Sneed JR, et al. Study design affects participant expectations: a survey. J Clin Psychopharmacol. 2009 Apr;29(2):179–181.
- Schedlowski M, Enck P, Rief W, et al. Neuro-bio-behavioral mechanisms of placebo and nocebo responses: implications for clinical trials and clinical practice. Pharmacol Rev. 2015 Jul;67(3):697–730.
- Leuchter AF, Hunter AM, Tartter M, et al. Role of pill-taking, expectation and therapeutic alliance in the placebo response in clinical trials for major depression. Br J Psychiatry. 2014 Dec;205(6):443–449.
- Baghai TC, Blier P, Baldwin DS, et al. General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry. Eur Arch Psychiatry Clin Neurosci. 2011 Nov;261(Suppl 3):207–245.
- Moller HJ. Antidepressants: controversies about their efficacy in depression, their effect on suicidality and their place in a complex psychiatric treatment approach. World J Biol Psychiatry. 2009;10(3):180–195.
- Fountoulakis KN, Moller HJ. Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. Int J Neuropsychopharmacol. 2011 Apr;14(3):405–412.
- Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. Plos Med. 2008 Feb;5(2):e45.
- Moller HJ. Standardised rating scales in psychiatry: methodological basis, their possibilities and limitations and descriptions of important rating scales. World J Biol Psychiatry. 2009;10(1):6–26.
- Walsh BT, Seidman SN, Sysko R, et al. Placebo response in studies of major depression: variable, substantial, and growing. JAMA. 2002 Apr 10;287(14):1840–1847.
- Fava M. The role of regulators, investigators, and patient participants in the rise of the placebo response in major depressive disorder. World Psychiatry. 2015 Oct;14(3):307–308.
- Kasper S, Dold M. Factors contributing to the increasing placebo response in antidepressant trials. World Psychiatry. 2015 Oct;14(3):304–306.
- Furukawa TA, Cipriani A, Atkinson LZ, et al. Placebo response rates in antidepressant trials: a systematic review of published and unpublished double-blind randomised controlled studies. Lancet Psychiatry. 2016 Nov;3(11):1059–1066.
- Hegerl U, Hautzinger M, Mergl R, et al. Effects of pharmacotherapy and psychotherapy in depressed primary-care patients: a randomized, controlled trial including a patients’ choice arm. Int J Neuropsychopharmacol. 2010 Feb;13(1):31–44.
- Niklson IA, Reimitz PE. Baseline characteristics of major depressive disorder patients in clinical trials in Europe and United States: is there a transatlantic difference? J Psychiatr Res. 2001 Mar–Apr;35(2):71–81.
- Pae CU, Wang SM, Han C, et al. Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder. J Psychiatry Neurosci. 2015 May;40(3):174–186.